within Pharmacolibrary.Drugs.ATC.C;

model C09DB02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.26,
    Cl             = 2.1666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02333333333333333,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.043,
    k12             = 14.1,
    k21             = 14.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09DB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Olmesartan medoxomil is an angiotensin II receptor antagonist (ARB) and amlodipine is a dihydropyridine calcium channel blocker. Co-formulated as a fixed-dose combination, this medication is used for treating hypertension (high blood pressure) in adults and children over 6 years. It is approved for current clinical use in many countries to help lower risk of cardiovascular events by controlling blood pressure.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers after oral administration of the combination tablet. PK values are reported separately for olmesartan and amlodipine.</p><h4>References</h4><ol><li><p>Scott, LJ, &amp; McCormack, PL (2008). Olmesartan medoxomil: a review of its use in the management of hypertension. <i>Drugs</i> 68(9) 1239–1272. DOI:<a href=\"https://doi.org/10.2165/00003495-200868090-00005\">10.2165/00003495-200868090-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18547134/\">https://pubmed.ncbi.nlm.nih.gov/18547134</a></p></li><li><p>Chen, X, et al., &amp; Zhao, Q (2012). Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. <i>Clinical drug investigation</i> 32(12) 783–790. DOI:<a href=\"https://doi.org/10.1007/s40261-012-0026-0\">10.1007/s40261-012-0026-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23160920/\">https://pubmed.ncbi.nlm.nih.gov/23160920</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09DB02;
